Showing papers in "Journal of Thrombosis and Haemostasis in 2006"

TL;DR: This document appraise the existing evidence on clinical and laboratory features of APS addressed during the forum and proposes amendments to the Sapporo criteria, including definitions on features ofAPS that were not included in the updated criteria.

TL;DR: Six categories of von Willebrand disease correlate with important clinical features and therapeutic requirements, and certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies.

TL;DR: A low pretest clinical score for HIT seems to be suitable for ruling out HIT in most situations (high‐negative predictive value), and the implications of an intermediate or high score vary in different clinical settings.

TL;DR: Fibrin sealants have been investigated as matrices to promote wound healing and are important determinants of angiogenesis and differ in their cell growth stimulation, clotting rate, and fibrin polymerization characteristics.

TL;DR: Compared the overall incidences of VT in the first half year in this study to the risk of major bleeding as described in the literature, prophylactic anti‐thrombotic treatment could be beneficial for patients with distant metastases.

TL;DR: Higher BS was related with increasing likelihood of VWD, and a mucocutaneous BS was strongly associated with bleeding after surgery or tooth extraction, which is potentially useful for a more accurate diagnosis of type 1 VWD.

TL;DR: The morbidity and mortality during 10’years after the first episode of VTE is high and not reduced by extension of secondary prophylaxis from 6 weeks to 6’months, and a strategy to reduce recurrence of V TE as well as mortality from arterial disease is needed.

TL;DR: A post‐treatment ADP‐induced platelet aggregation performed just before PCI identifies low responders to dual antiplatelet therapy with an increased risk of recurrent CV events.

TL;DR: The PFA‐100 closure time should be considered optional in the evaluation of platelet disorders and function, and its use in therapeutic monitoring of Platelet function is currently best restricted to research studies and prospective clinical trials.

TL;DR: The adapted ISTH DIC score may identify patients with severe sepsis who potentially benefit from high‐dose AT treatment, and may result in a significant mortality reduction.

TL;DR: Four‐week administration of dalteparin, 5000 IU once daily, after major abdominal surgery significantly reduces the rate of VTE, without increasing the risk of bleeding, compared with 1 week of thromboprophylaxis.

TL;DR: Plasma VWF levels are a more promising CHD risk factor in high‐risk populations with previous cardiovascular events, diabetes or old age, however, is it still unclear whetherVWF levels directly determine the rate and severity of arterial thrombus formation or whether they merely reflect alteration in other endothelial functions.

TL;DR: Increased levels of circulating EMP in CRF and HD patients represent a new marker of endothelial dysfunction in uremia, and the ability of p‐cresol and indoxyl sulfate to increase EMP release in vitro suggests that specific uremic factors may be involved in EMP elevation in patients.

TL;DR: When efficacy and safety were considered together, the oral, direct FXa inhibitor BAY 59‐7939 compared favorably with enoxaparin for the prevention of venous thromboembolism in patients undergoing elective total hip replacement.

TL;DR: Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.

TL;DR: In this paper, the authors studied the mortality, causes of death, and life expectancy of hemophilia patients between 1992 and 2001, compared with those of previous cohorts, together spanning the periods before, during, and after the use of potentially contaminated clotting products.

TL;DR: Certain circulating EMP phenotypes may be associated with severity, lesion volume and outcome of acute ischemic stroke and shows promising contribution to understanding stroke pathophysiology.

TL;DR: The prevalence of immune thrombocytopenic purpura in one populous state in the USA is comparable with that which has been reported in Europe.

TL;DR: Most boys with severe hemophilia A will probably have little bleeding and good joint function with tailored prophylaxis, while infusing less FVIII than usually required for traditional prophYLaxis.

TL;DR: In cancer patients, abnormal renal function, metastatic disease, recent major bleeding and recent immobility for ≥ 4 days are associated with an increased risk for both fatal PE and fatal bleeding.

TL;DR: A working definition for CECs is formulated based on CD146‐driven immunomagnetic isolation and a subsequent confirmatory step with Ulex‐Europaeus‐Lectin‐1 staining, which represents an important step toward consensus regarding the C ECs.

TL;DR: Adenine nucleotides, adenosine diphosphate (ADP), released from damaged cells and that are secreted from platelet‐dense granules, contribute to the positive feedback mechanism potentiating the platelet activation induced by physiological agonists such as collagen and thrombin.

TL;DR: The aim of this review article is to provide an overview of the biochemistry and physiology of angiogenin, specifically in relation to the human pathological states where angiagenin has been implicated and finally, its potential clinical applications.

TL;DR: Logistic regression analysis revealed that for postoperative heparin use a Charlson comorbidity score > 1 was an independent predictor of a major bleed and that vascular, general, and major surgery were associated with non‐significant trends towards an increased risk of major bleed.

TL;DR: In this large cohort, hemostatic factor and endothelial marker mean levels varied by race/ethnicity, even after adjustment for traditional CVD risk factors.

TL;DR: PCC administration is an effective treatment modality for the correction of warfarin anticoagulation in the urgent setting and advantages over FFP include more timely correction, absence of volume overload and potentially more complete correction.

TL;DR: These findings suggest that TF is not constitutively expressed in peripheral PMN, but can be up‐regulated and produced upon stimulation and specific gene transcription, as for instance during contact with activated platelets or endothelium.

TL;DR: It is concluded that ADAMTS‐13 is synthesized in human endothelial cells, and released constitutively, and the vast number of endothelium cells in the body may be an important source of ADAMts‐13.

TL;DR: This study convincingly demonstrated that the longer course of anticoagulants reduced the recurrence rate of venous thromboembolic twofold and confirmed that VTE is a chronic disease for which at least some affected patients remain at life-long risk.

TL;DR: Patients with VTE of unknown origin have a 60% higher risk of developing symptomatic atherosclerotic disease than do patients with secondary venous thrombosis and when the analysis was restricted to patients without previous symptomatic Atherosclerosis, the risk was reduced.